



DIVISION OF  
CORPORATION FINANCE

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549

February 18, 2020

Via E-mail

Jonathan Solomon  
Chief Executive Officer  
BiomX Inc.  
7 Pinhas Sapir St., Floor 2  
Ness Ziona, Israel 7414002

**Re: BiomX Inc.  
Form 8-K  
Exhibit No. 10.5 - Research and License Agreement, dated June 22, 2015, between BiomX Ltd. and Yeda Research and Development Company Limited, as amended  
Exhibit No. 10.6 - Exclusive Patent License Agreement dated April 25, 2017, between BiomX Ltd. and the Massachusetts Institute of Technology  
Exhibit No. 10.7 - Exclusive Patent License Agreement, dated December 15, 2017, among BiomX Ltd., Keio University and JSR Corporation, as amended  
Exhibit No. 10.8 - Exclusive Patent License Agreement, dated April 22, 2019, among BiomX Ltd., Keio University and JSR Corporation  
Exhibit no. 10.9 - Share Purchase Agreement, dated November 19, 2017, among BiomX Ltd., RondinX Ltd. and Guy Harmelin, as the Shareholders' Representative  
Filed November 1, 2019  
File No. 001-38762**

Dear Mr. Solomon:

We have concluded our assessment of your redacted exhibits for compliance with applicable form requirements and will process your supplemental response and related materials in accordance with your request.

Sincerely,

Division of Corporation Finance